Overview: Porphobilinogen Qualitative TestIntroduction: The Porphobilinogen Qualitative Test detects PBG to diagnose porphyria, causing abdominal pain or skin issues. Following 2023 APF guidelines, it uses biochemical methods for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected acute porphyria.
Other Names: PBG Urine Assay, Porphyria Screening Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Porphyria testing began in the 1950s with PBG detection methods. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects PBG to diagnose porphyria, guides treatment, and evaluates patients with abdominal pain or skin issues.
Test Parameters: 1. Porphobilinogen Presence
Pretest Condition: No fasting required. Collect random or 24-hour urine. Report history of abdominal pain, skin issues, or porphyria symptoms.
Specimen: Urine (sterile container, 5-20 mL), 24-Hour Urine (sterile container, 50-100 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document abdominal pain, skin issues, or family history of porphyria. Include current medications, especially barbiturates.
Consent: Written consent required, detailing the tests purpose, porphyria implications, and risks of sample collection.
Procedural Considerations: Uses colorimetric or chromatographic methods to detect PBG. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for porphyria diagnosis.
Factors Affecting Result Accuracy: Improper sample collection or light exposure can affect results. Medications may trigger PBG elevation.
Clinical Significance: Positive PBG confirms acute porphyria, guiding hemin therapy or trigger avoidance. Negative results may require total porphyrin testing.
Specialist Consultation: Consult a hepatologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Total porphyrins, ALA levels, or genetic testing to confirm porphyria diagnosis.
Test Limitations: Non-specific for certain porphyria types; clinical correlation is needed. Sample quality affects sensitivity.
References: APF Porphyria Guidelines, 2023; Blood, Anderson KE, 2022.
